http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2460462-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_199b2be2bae08fb08710a5ef557a7396
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B8-06
filingDate 2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2012-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b99d7f4ccd5a41be284c11cb5ef89dbb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_105b27bd7909fd713ac07c2a8bc089b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e656fdc7cc7bccc9e6439434aed8f3f2
publicationDate 2012-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2460462-C1
titleOfInvention Method of differential diagnostics of form of erectile dysfunction
abstract FIELD: medicine. n SUBSTANCE: invention relates to medicine, in particular to urology. Method includes carrying out ultrasonic Dopplerography (USDG) of vessels of penis, prostate gland and testicles before and after intake of medication which is inhibitor of phosphodiesterase-5 (IPDE-5) in average therapeutic dose and the following, after 1 hour, estimation of USDG-parameters. Mean total index of maximal blood flow in penis, prostate gland and testicles is calculated. Background indices of mean total blood flow are compared with average statistical age norm and with results of testing. If said index, reduced by 30% and more in comparison with norm, after testing increases by 60% and more, reversible form of vasculogenic erectile dysfunction is diagnosed. If similarly reduced background index increases by less than 30%, low-reversible form of vasculogenic erectile dysfunction is diagnosed. If normal or reduced by 20% and less background index increases by less than 30%, non-vasculogenic form of erectile dysfunction is diagnosed. n EFFECT: method ensures increase of accuracy of differential diagnostics of various forms of dysfunction, which specifies selection and prognosis of treatment. n 9 ex, 9 tbl
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2601405-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2535520-C1
priorityDate 2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007156183-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2336820-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2247533-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2139677-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1523244
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1523244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506374
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590271
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135400189
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID110635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582464
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135413547
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398744
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480192

Total number of triples: 29.